Latest research on Sensipar

Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. Cinacalcet is used to treat hyperparathyroidism (elevated parathyroid hormone levels), a consequence of parathyroid tumors and chronic renal failure.

Latest findings

According to the package insert for Sensipar (cinacalcet) (Amgen 2012), “serum calcium and serum phosphorus should be measured within 1 week and iPTH should be measured 1–4 weeks after initiation or dose adjustment of Sensipar®. [source, 2013]
The present analysis evaluates the serum P-lowering potential of cinacalcet, while controlling for PB and Vitamin D sterol changes, using data from the pan-European ECHO study (Evaluation of the Clinical Use of Mimpara in Haemodialysis and Peritoneal Dialysis Patients, an Observational Study). [source, 2013]
Thus, the drugs in our sample were: Lidocaine patch (Lidoderm, Endo Pharmaceuticals, Chadds Ford PA), Modafinil (Provigil, Cephalon, Frazer PA), cinacalcet (Sensipar, Amgen, Thousand Oaks CA), glatiramer (Copaxone, Teva, Petach Tikva, Israel) and Imatinib (Gleevec, Novartis, Basel, Switzerland). [source, 2012]
In 2004, the US Food and Drug Administration (FDA) approved cinacalcet (Sensipar) as the first calcimimetic drug for the treatment of SHPT. [source, 2012]
At the time of the procedure, his medications were Folic acid, Prednisone, Megestrol, Clonidine, Doxazosin, Lisinopril, Metoprolol, Minoxidil, Ranitidine, and Sensipar. [source, 2012]
For several years, the calcimimetic cinacalcet (Sensipar or Mimpara) has been used for the treatment of primary hyperparathyroidism (PHPT), hypercalcemia associated with parathyroid adenomas [5,6], parathyroid hyperplasia due to kidney disease [7] and parathyroid cancer [8]. [source, 2011]
They are potential drugs for treatment of various calcium metabolism disorders and one of them, Sensipar (cinacalcet) [9], is already in the market. [source, 2007]